Table 2

Tissue-to-plasma ratios of DIM and LTr1 in female CD-1 mice that received an oral dose of I3C (250 mg/kg)

Time (h)Tissue DIM (μg/g)/Plasma DIM (μg/ml)
LiverKidneyLungHeartBrain
0.2514.1 ± 5.75.6 ± 0.93.2 ± 2.12.6 ± 0.80.9 ± 0.3*
0.510.1 ± 2.14.7 ± 1.53.9 ± 1.03.3 ± 0.71.5 ± 0.7
0.7512.1 ± 10.24.5 ± 1.03.8 ± 1.04.0 ± 0.62.0 ± 0.6*
110.6 ± 6.06.7 ± 5.43.9 ± 1.83.6 ± 1.01.3 ± 0.4
25.0 ± 1.43.5 ± 0.73.0 ± 1.22.7 ± 1.01.3 ± 0.5
44.7 ± 1.03.1 ± 0.43.1 ± 1.82.8 ± 0.31.2 ± 0.3
68.0 ± 7.44.7 ± 3.04.5 ± 4.03.1 ± 0.61.4 ± 0.2
Tissue LTr1(μg/g)/plasma LTr1 (μg/ml)
16.8 ± 0.3ndndndnd
25.1 ± 2.23.3 ± 1.03.7 ± 0.62.6 ± 0.4nd
47.3 ± 2.74.7 ± 1.75.3 ± 3.73.8 ± 0.9nd
611.1 ± 9.44.8 ± 1.55.0 ± 0.64.1 ± 1.8nd
  • NOTE. Results are expressed as mean ± SD of three or four animals; ratios were calculated by taking the plasma and its respective tissue concentration in the same animal.

  • Abbreviations: DIM, 3,3′-diindolylmethane; LTr1, [2-(indol-3-ylmethyl)-indol-3-yl] indol-3-ylmethane; nd, not determined as the concentrations in two or more mice in the group at this time point were below the limit of quantification of the analytical method (0.1 μg/g tissue).

  • * Significant difference (P < 0.05) as determined by one-way ANOVA followed by Tukey’s post hoc test.